Hansa Biopharma Receives Ethics and Regulatory Clearance to Start Phase 2 Study of Imlifidase in Guillain Barré Syndrome
Lund, Sweden, April 15, 2019 – Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that it received Clinical Trial Application and Ethics Committee approvals in Europe for the company’s Phase 2 study of imlifidase in Guillain Barré Syndrome (GBS). The study will enroll up to 30 patients at approximately ten clinics in France, U.K. and the Netherlands over the next 18 months.GBS is a rare, acute, paralyzing, inflammatory disease of the peripheral nervous system that affects 1-2 in 100,000 people